ABT vs BSX
ABT and BSX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABTABBOTT LABORATORIES | BSXBOSTON SCIENTIFIC CORPORATION |
|---|---|---|
| Market cap | $187.78B | $71.48B |
| P/E (TTM) | 30.2 | 20.0 |
| P/B | 3.61 | 2.87 |
| P/S | 4.2x | 3.6x |
| Dividend yield | 2.19% | — |
| Revenue | $45.13B(TTM) | $21.00B(TTM) |
| Revenue growth (YoY) | 5.7% | 19.9% |
| Net income | $6.28B(TTM) | $3.67B(TTM) |
| Earnings growth (YoY) | -51.3% | 56.7% |
| EPS, diluted | $3.57(TTM) | $2.47(TTM) |
| EBIT margin | 18.2% | 18.0% |
| ROE | 12.5% | 11.6% |
| ROIC | 8.3% | 10.0% |
| Piotroski F | — | 8/9 |
| 1y total return | -16.6% | -52.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABT vs BSX
| Metric | ABT | BSX |
|---|---|---|
| End value | $30.6K | $25.2K |
| Total return | +206.0% | +152.1% |
| CAGR | +11.4% | +9.4% |
| Volatility | 24.0% | 27.4% |
| Sharpe | 0.41 | 0.32 |
| Sortino | 0.58 | 0.44 |
| Max drawdown | -39.6% | -60.6% |
Based on 2600 common trading days, 2016-04-06 → 2026-08-07 · risk-free 3.87% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)